BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment. 2021

Rui Zhang, and Heng Li, and Xianglei Zhang, and Jian Li, and Haixia Su, and Qiukai Lu, and Guangyu Dong, and Huixia Dou, and Chen Fan, and Zhanni Gu, and Qianwen Mu, and Wei Tang, and Yechun Xu, and Hong Liu
State Key Laboratory of Drug Research and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing, 100049, China.

Psoriasis is a kind of chronic inflammatory skin disorder, while the long-term use of conventional therapies for this disease are limited by severe adverse effects. Novel small molecules associated with new therapeutic mechanisms are greatly needed. It is known that phosphodiesterase 4 (PDE4) plays a central role in regulating inflammatory responses through hydrolyzing intracellular cyclic adenosine monophosphate (cAMP), making PDE4 to be an important target for the treatment of inflammatory diseases (e.g. psoriasis). In our previous work, we identified a series of novel PDE4 inhibitors with a tetrahydroisoquinoline scaffold through structure-based drug design, among which compound 1 showed moderate inhibition activity against PDE4. In this study, a series of novel tetrahydroisoquinoline derivatives were developed based on the crystal structure of PDE4D in complex with compound 1. Anti-inflammatory effects of these compounds were evaluated, and compound 36, with high safety, permeability and selectivity, exhibited significant inhibitory potency against the enzymatic activity of PDE4D and the TNF-α release from the LPS-stimulated RAW 264.7 and hPBMCs. Moreover, an in vivo study demonstrated that a topical administration of 36 achieved more significant efficacy than calcipotriol to improve the features of psoriasis-like skin inflammation. Overall, our study provides a basis for further development of tetrahydroisoquinoline-based PDE4 inhibitors against psoriasis.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000067996 RAW 264.7 Cells A transformed macrophage cell line isolated from ASCITES of mice infected with ABELSON MURINE LEUKEMIA VIRUS. RAW 264.7 Cell Line,264.7 Cell, RAW,264.7 Cells, RAW,Cell, RAW 264.7,Cells, RAW 264.7,RAW 264.7 Cell
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents

Related Publications

Rui Zhang, and Heng Li, and Xianglei Zhang, and Jian Li, and Haixia Su, and Qiukai Lu, and Guangyu Dong, and Huixia Dou, and Chen Fan, and Zhanni Gu, and Qianwen Mu, and Wei Tang, and Yechun Xu, and Hong Liu
Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
October 2015, Bioorganic & medicinal chemistry letters,
Rui Zhang, and Heng Li, and Xianglei Zhang, and Jian Li, and Haixia Su, and Qiukai Lu, and Guangyu Dong, and Huixia Dou, and Chen Fan, and Zhanni Gu, and Qianwen Mu, and Wei Tang, and Yechun Xu, and Hong Liu
Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
March 2021, European journal of medicinal chemistry,
Rui Zhang, and Heng Li, and Xianglei Zhang, and Jian Li, and Haixia Su, and Qiukai Lu, and Guangyu Dong, and Huixia Dou, and Chen Fan, and Zhanni Gu, and Qianwen Mu, and Wei Tang, and Yechun Xu, and Hong Liu
Design, Synthesis and Biological Evaluation of Novel Benzothiazole Derivatives as Selective PI3Kβ Inhibitors.
July 2016, Molecules (Basel, Switzerland),
Rui Zhang, and Heng Li, and Xianglei Zhang, and Jian Li, and Haixia Su, and Qiukai Lu, and Guangyu Dong, and Huixia Dou, and Chen Fan, and Zhanni Gu, and Qianwen Mu, and Wei Tang, and Yechun Xu, and Hong Liu
Novel 1,2,4-oxadiazole derivatives as selective butyrylcholinesterase inhibitors: Design, synthesis and biological evaluation.
January 2021, EXCLI journal,
Rui Zhang, and Heng Li, and Xianglei Zhang, and Jian Li, and Haixia Su, and Qiukai Lu, and Guangyu Dong, and Huixia Dou, and Chen Fan, and Zhanni Gu, and Qianwen Mu, and Wei Tang, and Yechun Xu, and Hong Liu
Synthesis, biological evaluation and molecular modelling studies on benzothiadiazine derivatives as PDE4 selective inhibitors.
February 2005, Bioorganic & medicinal chemistry,
Rui Zhang, and Heng Li, and Xianglei Zhang, and Jian Li, and Haixia Su, and Qiukai Lu, and Guangyu Dong, and Huixia Dou, and Chen Fan, and Zhanni Gu, and Qianwen Mu, and Wei Tang, and Yechun Xu, and Hong Liu
Design, synthesis and biological evaluation of novel pyridine derivatives as gut-selective NaPi2b inhibitors.
June 2022, Bioorganic & medicinal chemistry letters,
Rui Zhang, and Heng Li, and Xianglei Zhang, and Jian Li, and Haixia Su, and Qiukai Lu, and Guangyu Dong, and Huixia Dou, and Chen Fan, and Zhanni Gu, and Qianwen Mu, and Wei Tang, and Yechun Xu, and Hong Liu
Design, synthesis and biological evaluation of novel indole derivatives as gut-selective NaPi2b inhibitors.
July 2022, Bioorganic & medicinal chemistry,
Rui Zhang, and Heng Li, and Xianglei Zhang, and Jian Li, and Haixia Su, and Qiukai Lu, and Guangyu Dong, and Huixia Dou, and Chen Fan, and Zhanni Gu, and Qianwen Mu, and Wei Tang, and Yechun Xu, and Hong Liu
Design, synthesis and biological evaluation of novel cyclic malonamide derivatives as selective RIPK1 inhibitors.
February 2024, Bioorganic & medicinal chemistry letters,
Rui Zhang, and Heng Li, and Xianglei Zhang, and Jian Li, and Haixia Su, and Qiukai Lu, and Guangyu Dong, and Huixia Dou, and Chen Fan, and Zhanni Gu, and Qianwen Mu, and Wei Tang, and Yechun Xu, and Hong Liu
Design, synthesis, and biological evaluation of novel tryptanthrin derivatives as selective acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
February 2024, Bioorganic chemistry,
Rui Zhang, and Heng Li, and Xianglei Zhang, and Jian Li, and Haixia Su, and Qiukai Lu, and Guangyu Dong, and Huixia Dou, and Chen Fan, and Zhanni Gu, and Qianwen Mu, and Wei Tang, and Yechun Xu, and Hong Liu
Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors.
July 2020, Bioorganic chemistry,
Copied contents to your clipboard!